Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
Leonard A. Zwelling, Kurt W. Kohn(National Cancer Institute), Richard S. Ungerleider(Theradex Oncology (United States)), Margaret Nichols(National Institutes of Health), Stephen Michaels(National Institutes of Health), Leonard C. Erickson(National Institutes of Health)
Cited by 375
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531
Representation of older patients in cancer treatment trials
|Cancer|1994|349
Representation of African-Americans, Hispanics, and Whites in National Cancer Institute Cancer Treatment Trials
|JNCI Journal of the National Cancer Institute|1996|275
Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma
|JNCI Journal of the National Cancer Institute|1991|204